Botanix Pharmaceuticals (ASX:BOT) – Presentation to Botanix Advisory Board

Medical dermatology company Botanix Pharmaceuticals Limited (ASX:BOT) is pleased to release a presentation made at its Advisory Board meeting held on 19 January 2018. The presentation focused on the rapidly growing acne market and the positioning of the Company’s BTX 1503 product. The meeting was held with the Company’s advisers in Philadelphia, Pennsylvania ahead of the upcoming data from the BTX 1503 Phase 1b study. The presentation is available here for viewing.

Key highlights:

• Botanix convened an Advisory Board meeting on 19 January 2018 to review the clinical programs and market opportunities for its product portfolio
• The global acne market is estimated to reach US$7.3bn in 2025, with the top 2 leading acne products currently generating >US$1bn of sales in the US
• A topically applied product with a benign safety profile, multiple mechanisms of action and improved efficacy has the potential to generate significant revenues
• BTX 1503 has significant potential to address this market opportunity and first patient data is expected to be available in early Q1 2018

For more information, please visit www.botanixpharma.com or follow us on Twitter @BotanixPharma